Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carmopeptin is an oral digestive enzyme supplement developed by Med Manor Organics. It is formulated as a syrup and pediatric drops to manage digestive disorders, including indigestion (dyspepsia), flatulence, abdominal bloating, and stomach discomfort. The core active ingredients of Carmopeptin are alpha amylase (diastase) and papain. Alpha amylase is a digestive enzyme that breaks down complex carbohydrates and starches into simpler, easily absorbable sugars. Papain is a proteolytic enzyme derived from papaya that breaks down dietary proteins into smaller peptides and amino acids. Together, these enzymes support the body's natural digestive processes, particularly in cases of temporary enzyme insufficiency, chronic illness, or post-meal heaviness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Carmopeptin.